scholarly journals Title: Prematurity, the Diagnosis of Bronchopulmonary Dysplasia, and Maturation of Ventilatory Control Abbreviated Title: Control of Breathing and the Diagnosis of BPD

2020 ◽  
Author(s):  
Daniel Mammel ◽  
James Kemp
Keyword(s):  
Lung Disease ◽  
Bronchopulmonary Dysplasia ◽  
Ventilatory Support ◽  
Periodic Breathing ◽  
Supplemental Oxygen ◽  
Ventilatory Control ◽  
Plastic Process ◽  
Delayed Maturation ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Infants born before 32 weeks post-menstrual age (PMA) and receiving respiratory support at 36 weeks PMA are diagnosed with bronchopulmonary dysplasia. This label suggests that their need for supplemental oxygen is primarily due to acquired dysplasia of airways and airspaces, and that the supplemental oxygen (O2) is treating residual parenchymal lung disease. However, current approaches to ventilatory support in the first days of life, including artificial surfactant use and lower ventilating pressures have changed the pathology of chronic lung disease, and emerging evidence suggests that immature ventilatory control may also contribute to the need for supplemental oxygen at 36 weeks PMA. In all newborns, maturation of ventilatory control continues ex utero and is a plastic process. Supplemental O2 mitigates the hypoxemic effects of delayed maturation of ventilatory control, as well as reduces the duration and frequency of periodic breathing events. Prematurity is associated with altered and occasionally aberrant maturation of ventilatory control. Infants born prematurely, with or without a diagnosis of BPD, are more prone to long-lasting effects of dysfunctional ventilatory control. Awareness of the interaction between parenchymal lung disease and delayed maturation of ventilatory control is essential to understanding why a given premature infant requires and is benefitting from supplemental O2 at 36 weeks PMA.

ProSP-B as a potential biomarker in diffuse parenchymal lung disease (DPLD)

Pneumologie ◽  
2012 ◽  
Vol 66 (06) ◽  
Author(s):  
N Kahn ◽  
A Rossler ◽  
K Hornemann ◽  
T Muley ◽  
A Warth ◽  
...  
Keyword(s):  
Lung Disease ◽  
Potential Biomarker ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

scholarly journals Categorizing diffuse parenchymal lung disease in children

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Matthias Griese ◽  
Armin Irnstetter ◽  
Meike Hengst ◽  
Helen Burmester ◽  
Felicitas Nagel ◽  
...  
Keyword(s):  
Lung Disease ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

scholarly journals Genetic testing in diffuse parenchymal lung disease

2012 ◽  
Vol 7 (1) ◽  
pp. 79 ◽  
Author(s):  
Paolo Spagnolo ◽  
Fabrizio Luppi ◽  
Stefania Cerri ◽  
Luca Richeldi
Keyword(s):  
Genetic Testing ◽  
Lung Disease ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

scholarly journals Update in Diffuse Parenchymal Lung Disease 2011

2012 ◽  
Vol 186 (1) ◽  
pp. 24-29 ◽  
Author(s):  
Tracy R. Luckhardt ◽  
Joachim Müller-Quernheim ◽  
Victor J. Thannickal
Keyword(s):  
Lung Disease ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Imaging of Lung Disease, Part i: Focal and Diffuse Parenchymal Lung Diseases

2018 ◽  
Author(s):  
Gerald W. Staton Jr ◽  
Eugene A Berkowitz ◽  
Adam Bernheim
Keyword(s):  
Differential Diagnosis ◽  
Lung Disease ◽  
Clinical Information ◽  
Diffuse Lung Disease ◽  
Lipoid Pneumonia ◽  
Diffuse Parenchymal Lung Diseases ◽  
Parenchymal Disease ◽  
Parenchymal Lung Disease ◽  
Diffuse Lung ◽  
Parenchymal Lung

Parenchymal lung disease often presents on imaging with particular patterns that allow for recognition of certain clinical entities that may form the basis for an imaging differential diagnosis. Focal pulmonary opacities and multi-focal pulmonary opacities may be due to an infectious or neoplastic etiology, amongst other possibilities. Segmental/lobar opacities are also associated with a set of differential diagnoses. Diffuse parenchymal disease, while also associated with some infections and neoplasms, can additionally be seen in the setting of pneumoconioses and several idiopathic interstitial pneumonias. Combining clinical information including laboratory results with the imaging findings on chest radiography and computed tomography (CT) allows the physician to formulate an appropriate differential diagnosis or reach one specific diagnosis. This review contains 16 figures, 4 tables and 32 references Keywords: Pulmonary Opacity, Pulmonary Infection, Eosinophilic Pneumonia, Lipoid Pneumonia, Pulmonary Tuberculosis, Organizing Pneumonia, Lung Cancer, Diffuse Lung Disease, Pneumoconiosis, Idiopathic Interstitial Pneumonia

scholarly journals Analysis of pulmonary features and treatment approaches in the COPA syndrome

2018 ◽  
Vol 4 (2) ◽  
pp. 00017-2018 ◽  
Author(s):  
Jessica L. Tsui ◽  
Oscar A. Estrada ◽  
Zimu Deng ◽  
Kristin M. Wang ◽  
Christopher S. Law ◽  
...  
Keyword(s):  
Family History ◽  
Lung Disease ◽  
Alveolar Haemorrhage ◽  
Diffuse Alveolar Haemorrhage ◽  
Diffuse Parenchymal Lung Disease ◽  
History Of Disease ◽  
History Of ◽  
Parenchymal Lung Disease ◽  
Copa Syndrome ◽  
Parenchymal Lung

The COPA syndrome is a monogenic, autoimmune lung and joint disorder first identified in 2015. This study sought to define the main pulmonary features of the COPA syndrome in an international cohort of patients, analyse patient responses to treatment and highlight when genetic testing should be considered.We established a cohort of subjects (N=14) with COPA syndrome seen at multiple centres including the University of California, San Francisco, CA, USA. All subjects had one of the previously established mutations in the COPA gene, and had clinically apparent lung disease and arthritis. We analysed cohort characteristics using descriptive statistics.All subjects manifested symptoms before the age of 12 years, had a family history of disease, and developed diffuse parenchymal lung disease and arthritis. 50% had diffuse alveolar haemorrhage. The most common pulmonary findings included cysts on chest computed tomography and evidence of follicular bronchiolitis on lung biopsy. All subjects were positive for anti-neutrophil cytoplasmic antibody, anti-nuclear antibody or both and 71% of subjects had rheumatoid factor positivity. All subjects received immunosuppressive therapy.COPA syndrome is an autoimmune disorder defined by diffuse parenchymal lung disease and arthritis. We analysed an international cohort of subjects with genetically confirmed COPA syndrome and found that common pulmonary features included cysts, follicular bronchiolitis and diffuse alveolar haemorrhage. Common extrapulmonary features included early age of onset, family history of disease, autoantibody positivity and arthritis. Longitudinal data demonstrated improvement on chest radiology but an overall decline in pulmonary function despite chronic treatment.

Sign in / Sign up

Export Citation Format

Share Document